中国组织工程研究 ›› 2013, Vol. 17 ›› Issue (5): 805-810.doi: 10.3969/j.issn.2095-4344.2013.05.007

• 肾移植 kidney transplantation • 上一篇    下一篇

硼替佐米联合利妥昔单抗和血浆置换治疗高致敏等待肾移植患者

胡建敏,赵 明,李 民,郭 颖,陈 桦,刘永光   

  1. 南方医科大学珠江医院器官移植科,广东省广州市 510282
  • 收稿日期:2012-07-10 修回日期:2012-10-22 出版日期:2013-01-29 发布日期:2013-01-29
  • 通讯作者: 陈桦,硕士,主治医师,南方医科大学珠江医院器官移植科,广东省广州市 510282 chenhua302@hotmail.com
  • 作者简介:胡建敏☆,男,1979年生,江西省新干县人,汉族,2010年南方医科大学毕业,博士,主治医师,主要从事移植免疫和器官移植临床研究。 hjm1226@163.com

Bortezomib combined with rituximab and plasmapheresis for the treatment of highly sensitized renal transplant candidates

Hu Jian-min, Zhao Ming, Li Min, Guo Ying, Chen Hua, Liu Yong-guang   

  1. Department of Organ Transplantation, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, Guangdong Province, China
  • Received:2012-07-10 Revised:2012-10-22 Online:2013-01-29 Published:2013-01-29
  • Contact: Chen Hua, Master, Attending physician, Department of Organ Transplantation, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, Guangdong Province, China chenhua302@hotmail.com
  • About author:Hu Jian-min☆, Doctor, Attending physician, Department of Organ Transplantation, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, Guangdong Province, China hjm1226@163.com

摘要:

背景:高致敏是肾移植成功的障碍,目前肾移植脱敏治疗方法有静注免疫球蛋白、血浆置换、兔抗人淋巴细胞球蛋白等,但治疗效果常不满意。
目的:通过利妥昔单抗和硼替佐米进行肾移植后脱敏治疗,寻求效果满意的治疗方案。
方法:1例高致敏等待肾移植患者接受脱敏治疗,接受血浆置换2次后,立即给予利妥昔单抗500 mg静滴,2 d后开始分别在第1,4,8,11 天给予硼替佐米1.3 mg/m2,随访观察群体反应性抗体等变化。
结果与结论:随访的9个月中,患者群体反应性抗体从92%下降到17%,患者对利妥昔单抗和硼替佐米有良好的耐受性。初步经验表明:硼替佐米联合利妥昔单抗和血浆置换三联脱敏治疗方案可快速持久降低循环抗体水平,硼替佐米可能成为脱敏治疗方案中的重要要素。

关键词: 器官移植, 肾移植, 群体反应性抗体, 脱敏, 硼替佐米, 慢性肾小球肾炎, 利妥昔单抗, 免疫球蛋白, 兔抗人淋巴细胞球蛋白, 血浆置换, 特异性抗体

Abstract:

BACKGROUND: Highly sensitized is the barrier to successful renal transplantation. At present, the renal transplant desensitization treatment methods include the intravenous immunoglobulin, plasmapheresis and rabbit anti-human lymphocyte globulin, but the treatment effect is often unsatisfied.
OBJECTIVE: To perform the desensitization treatment through bortezomib and rituximab in order to find a treatment regimen with satisfactory results.
METHODS: One highly sensitized renal transplant candidate was selected to receive triple desensitization treatment. After plasmapheresis treatment, intravenous infusion of 500 mg rituximab was performed immediately. After infusion for 2 days, 1.3 mg/m2 bortezomib was injected at 1, 4, 8 and 11 days. The panel reactive antibody was observed during follow-up.
RESULTS AND CONCLUSION: During a nine-month follow-up period, cytotoxic panel reactive antibody decreased from 92% to17%. The patient represented no adverse effects. Our initial experience suggests that triple desensitization treatment of plasmapheresis, rituximab and bortezomib was effective to reduce circulating antibodies against human leucocyte antigen. Bortezomib may be useful in desensitization protocols.

Key words: organ transplantation, renal transplantation, reactive antibody, desensitization, bortezomib, chronic glomerulonephritis, rituximab monoclonal antibody, immunoglobulin, rabbit anti-human lymphocyte globulin, plasmapheresis, specific antibodies

中图分类号: